Development
Evaxion Biotech A/S
EVAX
$3.13
$0.5521.32%
NASDAQ
| 09/30/2023 | 06/30/2023 | 12/31/2022 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -- | -- | 8.21M | 7.32M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | 25.27M | 26.46M | |
| Operating Income | -- | -- | -25.27M | -26.46M | |
| Income Before Tax | -- | -- | -23.94M | -23.95M | |
| Income Tax Expenses | -- | -- | -772.00K | 724.00K | |
| Earnings from Continuing Operations | -- | -- | -23.17 | -24.67 | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | -23.17M | -24.67M | |
| EBIT | -- | -- | -25.27M | -26.46M | |
| EBITDA | -- | -- | -25.05M | -26.30M | |
| EPS Basic | -- | -- | -97.54 | -107.62 | |
| Normalized Basic EPS | -- | -- | -6.30 | -6.50 | |
| EPS Diluted | -- | -- | -97.54 | -107.62 | |
| Normalized Diluted EPS | -- | -- | -6.30 | -6.50 | |
| Average Basic Shares Outstanding | -- | -- | 9.50M | 9.26M | |
| Average Diluted Shares Outstanding | -- | -- | 949.90K | 925.80K | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |